Compare NTRA & DHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTRA | DHI |
|---|---|---|
| Founded | 2003 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.1B | 43.8B |
| IPO Year | 2015 | 1995 |
| Metric | NTRA | DHI |
|---|---|---|
| Price | $261.99 | $146.76 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 14 |
| Target Price | ★ $259.07 | $166.08 |
| AVG Volume (30 Days) | 1.3M | ★ 2.4M |
| Earning Date | 05-07-2026 | 04-21-2026 |
| Dividend Yield | N/A | ★ 1.19% |
| EPS Growth | ★ 0.65 | N/A |
| EPS | N/A | ★ 7.45 |
| Revenue | $210,939,000.00 | ★ $34,250,400,000.00 |
| Revenue This Year | $18.08 | $0.05 |
| Revenue Next Year | $19.65 | $5.85 |
| P/E Ratio | ★ N/A | $33.28 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $131.81 | $131.75 |
| 52 Week High | $288.04 | $183.62 |
| Indicator | NTRA | DHI |
|---|---|---|
| Relative Strength Index (RSI) | 52.98 | 41.87 |
| Support Level | $261.63 | $134.51 |
| Resistance Level | $288.04 | $150.06 |
| Average True Range (ATR) | 10.37 | 4.95 |
| MACD | -3.55 | -1.34 |
| Stochastic Oscillator | 23.31 | 29.15 |
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
D.R. Horton is the largest homebuilder in the United States with operations in 126 markets across 36 states. D.R. Horton mainly builds single-family homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. The firm has majority ownership of Forestar Group, a publicly traded residential lot development company. D.R. Horton's headquarters are in Arlington, Texas.